{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:16:06Z","timestamp":1773890166428,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008730","name":"The Norwegian Cancer Society","doi-asserted-by":"publisher","award":["100933"],"award-info":[{"award-number":["100933"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001840","name":"Rannis","doi-asserted-by":"publisher","award":["228683\\u2013051"],"award-info":[{"award-number":["228683\\u2013051"]}],"id":[{"id":"10.13039\/501100001840","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016242","name":"Childhood Cancer Association","doi-asserted-by":"publisher","award":["230001"],"award-info":[{"award-number":["230001"]}],"id":[{"id":"10.13039\/501100016242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016242","name":"Childhood Cancer Association","doi-asserted-by":"publisher","award":["190004"],"award-info":[{"award-number":["190004"]}],"id":[{"id":"10.13039\/501100016242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004257","name":"Western Norway Regional Health Authority","doi-asserted-by":"publisher","award":["F-12533"],"award-info":[{"award-number":["F-12533"]}],"id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["4462"],"award-info":[{"award-number":["4462"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016674","name":"NoVo Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005415","name":"H\u00e1sk\u00f3li \u00cdslands","doi-asserted-by":"publisher","award":["92252"],"award-info":[{"award-number":["92252"]}],"id":[{"id":"10.13039\/501100005415","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.tranon.2025.102628","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T20:09:27Z","timestamp":1765051767000},"page":"102628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Phenazine 5,10-dioxide analogues as potential therapeutics in AML: Efficacy on patient-derived blasts, in zebrafish larvae xenografts and synergy with venetoclax"],"prefix":"10.1016","volume":"63","author":[{"given":"Ingeborg Nerb\u00f8","family":"Reiten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7660-8678","authenticated-orcid":false,"given":"Reidun","family":"Aesoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3172-5608","authenticated-orcid":false,"given":"Jan-Lukas","family":"F\u00f8rde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7949-6460","authenticated-orcid":false,"given":"Goraksha Machhindra","family":"Khose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3585-0561","authenticated-orcid":false,"given":"Elvar \u00d6rn","family":"Viktorsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d8ystein","family":"Bruserud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e5l","family":"Rongved","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e5kon","family":"Reikvam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0353-3614","authenticated-orcid":false,"given":"Lars","family":"Herfindal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2025.102628_bib0001","first-page":"215","article-title":"Recherches sur la mati\u00e8re colorante des suppurations bleues: pyocyanine","volume":"51","author":"Fordos","year":"1860","journal-title":"CR Acad. Sci."},{"issue":"3","key":"10.1016\/j.tranon.2025.102628_bib0002","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1021\/cr020473j","article-title":"Phenazine natural products: biosynthesis, synthetic analogues, and biological activity","volume":"104","author":"Laursen","year":"2004","journal-title":"Chem. Rev."},{"issue":"4","key":"10.1016\/j.tranon.2025.102628_bib0003","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1039\/c2np00079b","article-title":"Phenazines and cancer","volume":"29","author":"Cimmino","year":"2012","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.tranon.2025.102628_bib0004","first-page":"273","article-title":"Chromobacterium iodinum (n. sp.)","volume":"100","author":"Davis","year":"1939","journal-title":"Zentralbl Bakteriol Parasitenkd Infekt. Hyg II Abt"},{"issue":"2","key":"10.1016\/j.tranon.2025.102628_bib0005","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3390\/md11020332","article-title":"Iodinin (1,6-dihydroxyphenazine 5,10-dioxide) from Streptosporangium sp. induces apoptosis selectively in myeloid leukemia cell lines and patient cells","volume":"11","author":"Myhren","year":"2013","journal-title":"Mar. Drugs"},{"issue":"5","key":"10.1016\/j.tranon.2025.102628_bib0006","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1039\/D1MD00020A","article-title":"New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells","volume":"12","author":"Viktorsson","year":"2021","journal-title":"RSC. Med. Chem."},{"issue":"7","key":"10.1016\/j.tranon.2025.102628_bib0007","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.bmc.2017.02.058","article-title":"Total synthesis and antileukemic evaluations of the phenazine 5,10-dioxide natural products iodinin, myxin and their derivatives","volume":"25","author":"Viktorsson","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.tranon.2025.102628_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117244","article-title":"Functionalized regioisomers of the natural product phenazines myxin and iodinin as potent inhibitors of mycobacterium tuberculosis and human acute myeloid leukemia cells","volume":"285","author":"Khose","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.tranon.2025.102628_bib0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bcmd.2012.10.005","article-title":"A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3","volume":"50","author":"Lichtman","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"issue":"12","key":"10.1016\/j.tranon.2025.102628_bib0011","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2025.102628_bib0012","unstructured":"FDA grants regul. approv. venetoclax comb. untreated acute myeloid leuk., 2025 (2020)."},{"issue":"15","key":"10.1016\/j.tranon.2025.102628_bib0013","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102628_bib0014","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.tranon.2025.102628_bib0015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.tranon.2025.102628_bib0016","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/bloodadvances.2023011964","article-title":"Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs","volume":"8","author":"Prosty","year":"2024","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.tranon.2025.102628_bib0017","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/ejh.14371","article-title":"Tumor lysis syndrome in acute myeloid leukemia patients treated with a venetoclax based regimen","volume":"114","author":"Rowe","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.tranon.2025.102628_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115820","article-title":"Venetoclax in adult acute myeloid leukemia","volume":"168","author":"Hu","year":"2023","journal-title":"Biomed. PharmacOther"},{"issue":"2","key":"10.1016\/j.tranon.2025.102628_bib0019","first-page":"47","article-title":"The impact of Gilteritinib on overall survival of adult patients with FLT3 positive acute myeloid leukemia: a systematic review","volume":"10","author":"Gupta","year":"2024","journal-title":"Princ Pr. Clin. Res."},{"issue":"1","key":"10.1016\/j.tranon.2025.102628_bib0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-024-01617-7","article-title":"Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML","volume":"17","author":"Cortes","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.tranon.2025.102628_bib0022","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41573-021-00210-8","article-title":"Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials","volume":"20","author":"Patton","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tranon.2025.102628_bib0023","series-title":"Drug Discovery, Design and Synthesis of Polycyclic Regulators of Cancer Cells and Nuclear Receptors: Phenazine 5,10-dioxides and Oxysterols","author":"Viktorsson","year":"2017"},{"issue":"6","key":"10.1016\/j.tranon.2025.102628_bib0024","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1089\/152581600750062372","article-title":"In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: studies of native AML blasts and AML cell lines","volume":"9","author":"Bruserud","year":"2000","journal-title":"J. Hematotherapy Stem Cell Res."},{"issue":"4","key":"10.1016\/j.tranon.2025.102628_bib0025","first-page":"416","article-title":"Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities","volume":"88","author":"Bruserud","year":"2003","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.tranon.2025.102628_bib0026","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1158\/1535-7163.MCT-17-1234","article-title":"A kinase inhibitor with anti-pim kinase activity is a potent and selective cytotoxic agent toward acute myeloid leukemia","volume":"18","author":"Bj\u00f8rnstad","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.tranon.2025.102628_bib0027","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.leukres.2006.02.014","article-title":"Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:bax ratio and low levels of heat shock protein 70 and 90","volume":"30","author":"Ryningen","year":"2006","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.tranon.2025.102628_bib0028","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/sj.leu.2400768","article-title":"Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23)","volume":"11","author":"Matsuo","year":"1997","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.tranon.2025.102628_bib0029","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ydbio.2017.07.017","article-title":"A defect in the mitochondrial protein Mpv17 underlies the transparent casper zebrafish","volume":"430","author":"D'Agati","year":"2017","journal-title":"Dev. Biol."},{"issue":"3","key":"10.1016\/j.tranon.2025.102628_bib0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/aja.1002030302","article-title":"Stages of embryonic development of the zebrafish","volume":"203","author":"Kimmel","year":"1995","journal-title":"Dev. Dyn."},{"issue":"1","key":"10.1016\/j.tranon.2025.102628_bib0031","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.xphs.2017.09.027","article-title":"Mechanistic physiologically based pharmacokinetic modeling of the dissolution and food effect of a biopharmaceutics classification system IV compound-the venetoclax story","volume":"107","author":"Emami Riedmaier","year":"2018","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.tranon.2025.102628_bib0032","doi-asserted-by":"crossref","DOI":"10.1242\/bio.059530","article-title":"A new software tool for computer assisted in vivo high-content analysis of transplanted fluorescent cells in intact zebrafish larvae","volume":"11","author":"F\u00f8rde","year":"2022","journal-title":"Biol. Open."},{"issue":"3","key":"10.1016\/j.tranon.2025.102628_bib0033","first-page":"587","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Proteom. Bioinform."},{"key":"10.1016\/j.tranon.2025.102628_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124989","article-title":"Liposomes loaded with daunorubicin and an emetine prodrug for improved selective cytotoxicity towards acute myeloid leukaemia cells","volume":"668","author":"Reiten","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.tranon.2025.102628_bib0035","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.leukres.2013.02.007","article-title":"CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation","volume":"37","author":"Zhu","year":"2013","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.tranon.2025.102628_bib0036","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/bjh.13572","article-title":"Absence of leukaemic CD34(+) cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered","volume":"171","author":"Zeijlemaker","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.tranon.2025.102628_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25126356","article-title":"Monocytic differentiation in acute myeloid leukemia cells: diagnostic criteria, biological heterogeneity, mitochondrial metabolism, resistance to and induction by targeted therapies","volume":"25","author":"Bruserud","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2025.102628_bib0038","series-title":"Advances in Precision Medicine Oncology","article-title":"Molecular-level understanding of the anticancer action mechanism of anthracyclines","author":"Charak","year":"2020"},{"issue":"8","key":"10.1016\/j.tranon.2025.102628_bib0039","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1021\/bi00758a003","article-title":"Inhibition of ribonucleic acid synthesis by myxin","volume":"11","author":"Hollstein","year":"1972","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.tranon.2025.102628_bib0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1021\/bi00779a023","article-title":"Interaction of phenazines with polydeoxyribonucleotides","volume":"10","author":"Hollstein","year":"1971","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.tranon.2025.102628_bib0041","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1021\/tx2004213","article-title":"DNA strand cleavage by the phenazine di-N-oxide natural product myxin under both aerobic and anaerobic conditions","volume":"25","author":"Chowdhury","year":"2012","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tranon.2025.102628_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122379","article-title":"A liposomal formulation of simvastatin and doxorubicin for improved cardioprotective and anti-cancer effect","volume":"629","author":"Bj\u00f8rnstad","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"12","key":"10.1016\/j.tranon.2025.102628_bib0044","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1038\/s41375-024-02405-5","article-title":"Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins","volume":"38","author":"Halilovic","year":"2024","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.tranon.2025.102628_bib0045","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s41388-023-02611-y","article-title":"Transgenic IDH2(R172K) and IDH2(R140Q) zebrafish models recapitulated features of human acute myeloid leukemia","volume":"42","author":"Wang","year":"2023","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.tranon.2025.102628_bib0046","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13807","article-title":"Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor","volume":"17","author":"Salem","year":"2024","journal-title":"Clin. Transl. Sci."},{"issue":"63","key":"10.1016\/j.tranon.2025.102628_bib0047","doi-asserted-by":"crossref","first-page":"107206","DOI":"10.18632\/oncotarget.22284","article-title":"Combined venetoclax and alvocidib in acute myeloid leukemia","volume":"8","author":"Bogenberger","year":"2017","journal-title":"Oncotarget."},{"issue":"20","key":"10.1016\/j.tranon.2025.102628_bib0048","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.21037\/atm-21-5066","article-title":"Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism","volume":"9","author":"Li","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"9","key":"10.1016\/j.tranon.2025.102628_bib0049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138377","article-title":"Mitochondrial profiling of acute myeloid leukemia in the assessment of response to apoptosis modulating drugs","volume":"10","author":"Ishizawa","year":"2015","journal-title":"PLoS. One"},{"issue":"17","key":"10.1016\/j.tranon.2025.102628_bib0050","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of released bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or Cytarabine in AML cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.tranon.2025.102628_bib0051","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-based therapies for acute myeloid leukemia","volume":"32","author":"Guerra","year":"2019","journal-title":"Best Pr. Res Clin Haematol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102628_bib0052","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","article-title":"FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation","volume":"6","author":"Zhu","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.tranon.2025.102628_bib0053","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41375-018-0201-2","article-title":"The MCL1-specific inhibitor S63845 acts synergistically with venetoclax\/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells","volume":"33","author":"Li","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2025.102628_bib0054","first-page":"1","article-title":"Venetoclax and new BCL-2 inhibitors in acute myeloid leukemia","author":"Niscola","year":"2025","journal-title":"Expert Opin. PharmacOther"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325003596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325003596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:50:33Z","timestamp":1773877833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523325003596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":51,"alternative-id":["S1936523325003596"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102628","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phenazine 5,10-dioxide analogues as potential therapeutics in AML: Efficacy on patient-derived blasts, in zebrafish larvae xenografts and synergy with venetoclax","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102628"}}